Sexual Dysfunction

Positive results reported on phase II study of LibiGel

Published in Biotech Business Week, October 18th, 2004

Antares Pharma, Inc., (ANTR) announced that its topical testosterone gel North American licensee, BioSante Pharmaceuticals, Inc., (BPA), reported that its placebo-controlled phase II study showed that treatment with LibiGel significantly increased satisfying sexual events in surgically menopausal women suffering from female sexual dysfunction (FSD).

This announcement follows a recent decision by the U.S. Food and Drug Administration (FDA) to grant Procter & Gamble fast track status for its formulation of Intrinsa, an investigational female testosterone patch, based upon data for its two phase III trials.

LibiGel utilizes Antares Pharma's propriety...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2004-10-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry